Lyfstone, a Medtech company that develops diagnostic tests for the field of orthopaedics. Orthopaedics is a field of medicine where modern, diagnostic tools have had very little impact, and where many relevant diagnostic tools are unknown or very little used. The company is focussing on joint implant revisions, and has identified a biomarker having a range of relevant utilities (most important infection and aseptic loosening) in this patient group.
Lyfstone has established the scientific and clinical basis for the use of the biomarker for diagnosis of infection and aseptic loosening in implant revisions. The biomarker will be commercialized on an in-licensed Point of Care / Lateral Flow Device platform.
“With the help of NOME’s elite network of mentors we hope to get strategic advice and connections to potential investors to fast track the growth of our business”
Lyfstone is headed by CEO Stein Lian who has a large, international network of clinical, scientific and business advisors. Lyfstone is located in Tromsø, Norway and joined NOME in 2017.